checkAd
    Startseite > Aktien > FibroGen > Nachrichten
    FibroGen Aktie
    1,0815
     
    EUR
    -6,36 %
    -0,0735 EUR
    Letzter Kurs 10.05.24 Tradegate
    1,0475
     
    EUR
    2.864 STK
    Geldkurs 10.05.24
    1,1160
     
    EUR
    2.687 STK
    Briefkurs 10.05.24
    ISIN: US31572Q8087 · WKN: A12EZ0 · SYM: 1FG · USA

    Neueste Nachrichten

    FibroGen to Participate in Upcoming Investor Conferences
    07.05.24 · globenewswire · FibroGen
    FibroGen Reports First Quarter 2024 Financial Results
    06.05.24 · globenewswire · FibroGen
    FibroGen to Report First Quarter 2024 Financial Results
    29.04.24 · globenewswire · FibroGen
    FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology
    24.04.24 · globenewswire · FibroGen
    FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
    02.04.24 · globenewswire · FibroGen
    FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
    26.03.24 · globenewswire · FibroGen
    FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
    11.03.24 · globenewswire · FibroGen
    FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
    26.02.24 · globenewswire · FibroGen
    FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
    26.02.24 · globenewswire · FibroGen
    FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
    20.02.24 · globenewswire · FibroGen
    FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
    05.02.24 · globenewswire · FibroGen
    FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
    25.01.24 · globenewswire · FibroGen